CLZ-8
CLZ-8 (Compound 8) is an orally active Mcl-1-PUMA interface inhibitor, with a Ki of 0.3 μM. CLZ-8 exhibits dual activity on reduce PUMA-dependent apoptosis while deactivating Mcl-1-mediated anti-apoptosis in cancer cells[1].
Product Specifications
CAS Number
678158-55-9
UNSPSC
12352005
Target
Apoptosis; Bcl-2 Family
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/clz-8.html
Purity
99.14
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1N=C(N2CCN(CCO)CC2)S/C1=C\C3=CC=C(C4=CC=CC=C4)C=C3
Molecular Formula
C22H23N3O2S
Molecular Weight
393.50
References & Citations
[1]Liu J, et al. Targeting the apoptotic Mcl-1-PUMA interface with a dual-acting compound. Oncotarget. 2017 Apr 20;8 (33) :54236-54242.|[2]Feng T, et al. CLZ-8, a potent small-molecular compound, protects radiation-induced damages both in vitro and in vivo. Environ Toxicol Pharmacol. 2018 Jul;61:44-51.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Mcl-1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
abx551596 96 Tests
Mouse Translin-associated protein X (TSNAX) ELISA Kit
Sign In for Pricing
View Details 36-2168-20 20 µg
Anti-Dystrophin (DMD) (Marker of Duchenne and Becker Muscular Dystrophy) Monoclonal Antibody (Clone: DMD/3244)
Sign In for Pricing
View Details 